Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

The smart money seems to be calling a bottom for the healthcare sector. That could mean it’s time for investors to start taking another look at the industry’s more beleaguered stocks. Since the start ...